Search

IT has been shown that bovine semen—as well as that of man, dog, rat and cock—displays, among its manifold non-gametic biological activities1, a constant and fairly strong pituitary-inhibiting action1–3. This effect does not seem to be proportional to the very low androgenic activity of the semen. Its relation to the well-established œstrogenic activities appears also always to be questionable2.

This document provides information on a clinical trial, NCT06255392, for the treatment of HER2-negative advanced breast cancer patients without precise treatment targets. The trial aims to extend combination target therapy involving PARP inhibitors and anti-angiogenesis to all patients with homologous recombination repair defects (HRD-positive). The phase III randomized clinical study will investigate the effectiveness of the combination therapy of PARP inhibitor "fludzoparib" and anti-angiogenic "apatinib" in treating HRD-positive/HER2-negative advanced breast cancers. The trial will assess various outcome measures, including progression-free survival, objective response rate, clinical benefit rate, disease control rate, overall survival time, rate of adverse events, and quality of life scale score. The trial is expected to enroll 200 adult female patients and is estimated to be completed by March 2031. [Extracted from the article]

Breast cancer is the most common cancer in Canadian women, including those of reproductive age. (1) About 50% of women aged 40 years or younger in developed countries currently diagnosed [...]

Byline: Kimihiko. Ito, Hiroshi. Tsubamoto, Kayo. Inoue, Yukari. Miyoshi, Yoshihiro. Ito, Kensuke. Hori Objectives: We conducted a retrospective multi-institutional study to evaluate the efficacy and toxicity of intraperitoneal or intrapleural [...]